Mila Petrova

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 196 citations · Full text

Overall Survival, Gastrointestinal Oncology, Medicine +7

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

Susana Banerjee, Raffaele Califano, J. Corral et al. · Annals of Oncology · 2017 · 136 citations · Full text

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer

Mila Petrova, Mariyana Eneva, Jeliazko Arabadjiev et al. · BioScience Trends · 2020 · 54 citations · Full text

Multicentric Retrospective Study, Immunology, Metastatic Nsclc +18

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer

Mila Petrova, Ivan Donev, Maria Radanova et al. · Clinical & Experimental Immunology · 2020 · 35 citations · Full text

Surgical Oncology, High Nlr, Immunology +18

Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer

Shah Zeb Khan, Luca Arecco, Cynthia Villarreal‐Garza et al. · JCO Global Oncology · 2022 · 26 citations · Full text